Wells Fargo’s Carisma Therapeutics CARM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-19,371
| Closed | -$44K | – | 6965 |
|
|
2024
Q1 | $44K | Buy |
19,371
+11,209
| +137% | +$26.9K | ﹤0.01% | 5309 |
|
|
2023
Q4 | $23.9K | Buy |
8,162
+1,175
| +17% | +$3.49K | ﹤0.01% | 5572 |
|
|
2023
Q3 | $29.6K | Sell |
6,987
-3,611
| -34% | -$22.9K | ﹤0.01% | 5436 |
|
|
2023
Q2 | $92.9K | Buy |
10,598
+10,083
| +1,958% | +$54.9K | ﹤0.01% | 5091 |
|
|
2023
Q1 | $1.6K | Sell |
515
-24
| -4% | -$229 | ﹤0.01% | 6263 |
|
|
2022
Q4 | $6.58K | Buy |
539
+2
| +0.4% | +$21 | ﹤0.01% | 5694 |
|
|
2022
Q3 | $5K | Sell |
537
-8,927
| -94% | -$122K | ﹤0.01% | 5890 |
|
|
2022
Q2 | $153K | Buy |
9,464
+7,244
| +326% | +$82.9K | ﹤0.01% | 4422 |
|
|
2022
Q1 | $27K | Sell |
2,220
-3,214
| -59% | -$44.9K | ﹤0.01% | 5902 |
|
|
2021
Q4 | $89K | Sell |
5,434
-12,823
| -70% | -$258K | ﹤0.01% | 5703 |
|
|
2021
Q3 | $289K | Buy |
18,257
+10,826
| +146% | +$520K | ﹤0.01% | 4945 |
|
|
2021
Q2 | $687K | Sell |
7,431
-14,436
| -66% | -$921K | ﹤0.01% | 4451 |
|
|
2021
Q1 | $1.14M | Buy |
21,867
+12,205
| +126% | +$576K | ﹤0.01% | 4159 |
|
|
2020
Q4 | $260K | Buy |
9,662
+9,583
| +12,130% | +$243K | ﹤0.01% | 4942 |
|
|
2020
Q3 | $2K | Buy |
79
+4
| +5% | +$80 | ﹤0.01% | 6121 |
|
|
2020
Q2 | $1K | Hold |
75
| – | – | ﹤0.01% | 6155 |
|
|
2020
Q1 | $0 | Buy |
75
+32
| +74% | +$524 | ﹤0.01% | 6217 |
|
|
2019
Q4 | $1K | Sell |
43
-4,912
| -99% | -$113K | ﹤0.01% | 6234 |
|
|
2019
Q3 | $116K | Sell |
4,955
-44
| -0.9% | -$1.03K | ﹤0.01% | 5247 |
|
|
2019
Q2 | $150K | Buy |
4,999
+4,913
| +5,713% | +$147K | ﹤0.01% | 5121 |
|
|
2019
Q1 | $2K | Hold |
86
| – | – | ﹤0.01% | 5850 |
|
|
2018
Q4 | $2K | Sell |
86
-156
| -64% | -$4.98K | ﹤0.01% | 6189 |
|
|
2018
Q3 | $10K | Buy |
+242
| New | +$9.43K | ﹤0.01% | 5986 |
|
|
2015
Q3 | – | Sell |
-40
| Closed | -$2K | – | 6212 |
|
|
2015
Q2 | $2K | Buy |
40
+24
| +150% | +$3.39K | ﹤0.01% | 6152 |
|
|
2015
Q1 | $3K | Sell |
16
-20
| -56% | -$4.37K | ﹤0.01% | 5906 |
|
|
2014
Q4 | $9K | Hold |
36
| – | – | ﹤0.01% | 5664 |
|
|
2014
Q3 | $8K | Buy |
36
+15
| +71% | +$3.56K | ﹤0.01% | 5670 |
|
|
2014
Q2 | $5K | Buy |
+21
| New | +$5.2K | ﹤0.01% | 5794 |
|
Other funds holding CARM
TOTUOP
TGA
Wells Fargo's CARM Position: Q2 2024 in Review
Wells Fargo sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 19,371 shares — an estimated $44K sold.
Wells Fargo first reported a position in CARM in Q2 2014 and held it in 28 quarters. The position peaked at $1.14M in Q1 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.
- Wells Fargo reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 19,371 Carisma Therapeutics shares in Q2 2024, an estimated $44K.
- Wells Fargo first reported a position in Carisma Therapeutics in Q2 2014 and held it in 28 quarters.
- Wells Fargo's Carisma Therapeutics position peaked at $1.14M in Q1 2021.
- 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.